Saturday 17 October 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024. In the quarter to June 2026, revenue grew 555.6%, EPS fell 5.88%, free cash flow grew 10.6% and total debt rose 372.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.45
0.30
−6.32%
Follow NUVB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 9.55 | 7.30 | 1.59 | 0.95 | 1.43 | 1.54 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 12.52 | 15.23 | 8.88 | 2.55 | 4.16 | 9.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 5 | 36 | 64 | 53 | 51 | 220 | 298 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.21 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 8 | 63 | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 10.10 | 85.22 | |||||
| EBT | — | — | — | — | (42) | (87) | (104) | (76) | (568) | (205) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (7,213.76) | (325.31) | |||||
| Net income | — | 0 | — | 0 | (42) | (87) | (104) | (76) | (568) | (205) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 1 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.18 | ||||
| Earnings | — | — | — | — | (0.43) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) | |||||
| Cash flow | — | — | — | — | (0.37) | (0.34) | (0.44) | (0.31) | (0.49) | (0.51) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | |||||
| Free cash flow | — | — | — | — | (0.38) | (0.35) | (0.45) | (0.31) | (0.49) | (0.53) | |||||
| Book value | — | — | — | — | 2.21 | 3.77 | 3.02 | 2.76 | 1.73 | 0.90 | |||||
| Shares, m | — | — | — | — | 98 | 198 | 217 | 219 | 269 | 342 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 48.65 | |||||
| P/B | — | — | — | — | — | — | — | — | 1.54 | 10.01 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 41.08 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (1.69) | (14.87) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (37) | (68) | (96) | (68) | (130) | (173) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | 0 | (8) | |||||
| Free cash flow | — | — | — | — | (37) | (68) | (96) | (68) | (131) | (182) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 214 | 755 | 654 | 602 | 468 | 489 | ||||
| Total debt | — | — | — | — | — | 3 | 4 | — | 6 | 53 | |||||
| Net debt | — | — | — | — | (216) | (762) | (657) | (611) | (496) | (476) | |||||
| Shareholders’ equity | — | — | — | — | 215 | 746 | 655 | 605 | 464 | 306 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (37.57) | (17.41) | (14.39) | (11.72) | (97.74) | (36.04) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | (8.67) | (18.07) | (14.87) | (12.03) | (106.27) | (53.18) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Nuvation Bio Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SEPN Septerna, Inc. | $1.8B | — (loss-making) | — (loss-making) | +22,375.63% (above 0%: growing) | n/m | −9.01% (below 0%: shrinking) | 100.00% | (62.95%) | Compare |
| BHVN Biohaven Ltd. | $1.7B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +49.13% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.7B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NUVB Nuvation Bio Inc. | $1.7B | — (loss-making) | — (loss-making) | +555.64% (above 0%: growing) | n/m | +10.62% (above 0%: growing) | 70.11% | (161.06%) | |
| ZBIO Zenas BioPharma, Inc. | $1.7B | — (loss-making) | — (loss-making) | — | n/m | −37.12% (below 0%: shrinking) | 100.00% | (10,765.90%) | Compare |
| OCUL Ocular Therapeutix, Inc. | $1.6B | — (loss-making) | — (loss-making) | +0.12% (above 0%: growing) | n/m | −25.35% (below 0%: shrinking) | 85.08% | (609.34%) | Compare |
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −46.23% (below 0%: shrinking) | n/m | +15.05% (above 0%: growing) | 100.00% | (1,472.25%) | Compare |
| STOK Stoke Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −32.51% (below 0%: shrinking) | n/m | −128.97% (below 0%: shrinking) | 100.00% | (701.65%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.6B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $1.6B | — | — | +0.12% | — | −31.23% | 92.54% | (336.14%) |
Nuvation Bio Inc. (NUVB) key facts
- Strength: Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024.
- Nuvation Bio Inc. (NUVB) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, NUVB traded at $4.45, a market capitalization of $1.7 billion.
- Return on equity was −53.2% and debt-to-equity 0.98.
- Its Altman Z-score is 3.64 (safe zone) for fiscal 2025.